TherapeuticsMD Inc
TXMD1.700USD
+0.030+1.80%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
19.68MMarket Cap
64.96P/E TTM
More Details of TherapeuticsMD Inc Company
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
TherapeuticsMD Inc Info
Ticker SymbolTXMD
Company nameTherapeuticsMD Inc
IPO dateJan 31, 2001
CEOWalker (Marlan D)
Number of employees1
Security typeOrdinary Share
Fiscal year-endJan 31
Address951 Yamato Road, Suite 220
CityBOCA RATON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33431
Phone15619611900
Websitehttps://www.therapeuticsmd.com/
Ticker SymbolTXMD
IPO dateJan 31, 2001
CEOWalker (Marlan D)
Company Executives of TherapeuticsMD Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
--
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Non-U.S
642.00K
67.44%
United States
310.00K
32.56%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.26%
Tejara Capital Ltd.
2.97%
Adar1 Capital Management LLC
1.81%
Other
76.17%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
10.30%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.26%
Tejara Capital Ltd.
2.97%
Adar1 Capital Management LLC
1.81%
Other
76.17%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.44%
Investment Advisor
7.63%
Individual Investor
1.55%
Investment Advisor/Hedge Fund
1.39%
Research Firm
1.13%
Other
69.86%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
82
3.26M
28.17%
-348.35K
2025Q2
88
5.28M
45.63%
+1.46M
2025Q1
93
3.58M
30.94%
-393.28K
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
2023Q2
299
4.48M
44.55%
-545.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
1.19M
10.3%
-1.75M
-59.54%
Jun 30, 2025
Clearline Capital LP
635.22K
5.49%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
379.00K
3.27%
-2.94K
-0.77%
Jun 30, 2025
Tejara Capital Ltd.
344.25K
2.97%
-341.00
-0.10%
Jun 30, 2025
Adar1 Capital Management LLC
209.21K
1.81%
-60.95K
-22.56%
Jun 30, 2025
Morgan Stanley & Co. LLC
130.12K
1.12%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
109.08K
0.94%
-2.42K
-2.17%
Jun 30, 2025
Walker (Marlan D)
73.64K
0.64%
+2.79K
+3.94%
Apr 18, 2025
Collins (Cooper C)
60.52K
0.52%
--
--
Apr 18, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
Date
Type
Ratio
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
May 06, 2022
Merger
50→1
FAQs
Who are the top five shareholders of TherapeuticsMD Inc?
The top five shareholders of TherapeuticsMD Inc are:
Rubric Capital Management LP holds 1.19M shares, accounting for 10.30% of the total shares.
Clearline Capital LP holds 635.22K shares, accounting for 5.49% of the total shares.
The Vanguard Group, Inc. holds 379.00K shares, accounting for 3.27% of the total shares.
Tejara Capital Ltd. holds 344.25K shares, accounting for 2.97% of the total shares.
Adar1 Capital Management LLC holds 209.21K shares, accounting for 1.81% of the total shares.
Rubric Capital Management LP holds 1.19M shares, accounting for 10.30% of the total shares.
Clearline Capital LP holds 635.22K shares, accounting for 5.49% of the total shares.
The Vanguard Group, Inc. holds 379.00K shares, accounting for 3.27% of the total shares.
Tejara Capital Ltd. holds 344.25K shares, accounting for 2.97% of the total shares.
Adar1 Capital Management LLC holds 209.21K shares, accounting for 1.81% of the total shares.
What are the top three shareholder types of TherapeuticsMD Inc?
The top three shareholder types of TherapeuticsMD Inc are:
Rubric Capital Management LP
Clearline Capital LP
The Vanguard Group, Inc.
Rubric Capital Management LP
Clearline Capital LP
The Vanguard Group, Inc.
How many institutions hold shares of TherapeuticsMD Inc (TXMD)?
As of 2025Q3, 82 institutions hold shares of TherapeuticsMD Inc, with a combined market value of approximately 3.26M, accounting for 28.17% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.46%.
What is the biggest source of revenue for TherapeuticsMD Inc?
In FY2025Q2, the -- business generated the highest revenue for TherapeuticsMD Inc, amounting to -- and accounting for --% of total revenue.
